NextCure, Inc. (NXTC) key performance indicators and operating metrics (2 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Weighted-Average Shares Outstanding Basic and Diluted | 5.24M | FY2026-Q1 |
| Current LNCB74 Phase 1 Dose Escalation Cohort Being Dosed | 4.00 | FY2025-Q2 |
Back to NXTC overview · NXTC earnings · NXTC holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.